Cagrilintide is a long-acting amylin analog developed for once-weekly study. It belongs to a different signaling category from GLP-1 receptor agonists, even though later clinical programs have evaluated cagrilintide together with semaglutide.
Key takeaways
- Cagrilintide is an amylin analog; semaglutide is a GLP-1 receptor agonist.
- Single-agent phase 2 evidence should be distinguished from later CagriSema combination trials.
- As of the reviewed FDA information, cagrilintide is not a component of an FDA-approved drug.
Why amylin is a distinct research pathway
Amylin is co-secreted with insulin and participates in nutrient-related signaling. Cagrilintide was engineered for extended exposure relative to native amylin. Its receptor pharmacology and molecular design are not interchangeable with GLP-1, GIP or glucagon receptor agonism.
What the phase 2 trial contributes
The randomized phase 2 trial compared multiple cagrilintide dose groups with placebo and an active comparator in adults with overweight or obesity. It assessed change in body weight and safety over the study period. The paper supported continued development but did not make cagrilintide an approved medicine.
When summarizing the trial, the useful details are population, randomization, comparator, duration, primary endpoint and adverse-event pattern. Copying a maximum percentage without those qualifiers is not an adequate evidence review.
Single agent is not the same as CagriSema
CagriSema refers to coadministration of cagrilintide and semaglutide in specified clinical programs. Results from that combination cannot be presented as cagrilintide-only results, and neither dataset validates an independently supplied blend unless equivalence and product quality are established.
Sources & editorial method
The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.
2 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Once-weekly cagrilintide for weight management in people with overweight and obesityLau DCW, et al. The Lancet. 2021;398:2160–2172. PMID 34798060 · DOI 10.1016/S0140-6736(21)01751-7
- FDA concerns with unapproved GLP-1 drugs used for weight lossU.S. Food and Drug Administration. Content current through May 31, 2026.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
